Home Clinical Topics FDA approves new radiopharmaceutical for certain GI cancers

FDA approves new radiopharmaceutical for certain GI cancers

Author(s):

On Jan. 26, the U.S. Food and Drug Administration (FDA) approved the first radiopharmaceutical, Lutathera (lutetium Lu 177 dotatate), for the treatment of gastroenteropancreatic neuroendocrine tumors.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here